期刊文献+

以磺丁基醚-β-环糊精为渗透活性物质的盐酸氨溴索渗透泵片的制备 被引量:3

Preparation of osmotic pump tablets of ambroxol hydrochloride using sulfobutylether-β-cyclodextrin as an osmotically active substance
原文传递
导出
摘要 目的:以新型辅料磺丁基醚-β-环糊精(SBE-β-CD)作为渗透活性物质制备盐酸氨溴索渗透泵片,并对其释药机制进行初步探讨。方法:考察不同的渗透压活性物质对药物释放的影响,并通过正交设计试验确定了最优处方。结果:SBE-β-CD与常用的渗透压活性物质相比,具有显著优越性,制备的渗透泵片体外释药速率稳定,符合零级释药方程,且12 h累积释药率达到85%以上。结论:SBE-β-CD可以作为一种新型渗透活性物质,且制备的盐酸氨溴索渗透泵片是以渗透泵为主要的释药机制。 Objective: To prepare osmotic pump tablets of ambroxol hydrochloride using sulfobutylether-β-cyclodextrin as an osmotically active substance,and to investigate the mechanisms of drug release from the osmotic pump tablets.Methods: Influence of different osmotically active substances on drug release was studied.The optimal formulation was selected by orthogonal experiment.Results: Compared to general osmotically active substances,SBE-β-CD had marked superiority.The release of ambroxol hydrochloride was stable,and accorded with zero order release.The cumulative release percentage at 12 h reached up to 85%.Conclusion: SBE-β-CD can be used as a new osmotically active substance.The main mechanism of drug release from osmotic pump tablets is osmotic pump.
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第18期2212-2216,共5页 Chinese Journal of New Drugs
基金 石药集团医药联合研究基金(c2011206172)
关键词 磺丁基醚-Β-环糊精 渗透活性物质 渗透泵片 释药机制 盐酸氨溴索 sulfobutylether-β-cyclodextrin osmotically active substance osmotic pump tablet mecha-nisms of releasing drug ambroxol hydrochloride
  • 相关文献

参考文献14

  • 1KUMAR P, MISHRA B. An overview of recent patents on oral os- motic drug delivery systems[ J]. Recent Pat Drug Deliv Formul, 2007,1 ( 3 ) :236 - 255.
  • 2GUPTA BP,THAKUR N,JAIN NP,et al. Osmotically controlled drug delivery system with associated drugs [ J ]. J Pharm Pharm Sci,2010,13(4) :571 -588.
  • 3SETO Y, OCHI M, IGARASHI N,et al. In vitro photobiochemical characterization of sulfobutylether--cyclodextrin formulation of bufexamac[ J]. J Pharm Biomed Anal,2011,55(3) :591 -596.
  • 4STELLA VJ,RAJEWSKI RA. Derivatives of cycldextrins exhibi- ting enhanced aqueous solubility and the pharmaceutical use thereof: US ,5134127 [ P ]. 1992 - 07 - 28.
  • 5ZANNOU EA,STRENG WH,STELLA VJ. Osmotic propertics of sulfobutylether and hydroxypropyl cyclodextrins[J]. Pharm Res, 2001,18(8) :1226 - 1231.
  • 6OKIMOTO K,RAJEWSKI RA,STELLA VJ. Release of testoster- one from an osmotic pump tablet utilizing (SBE) 7m-beta-cyc,o- dextrin as both a solubilizing and an osmotic pump agent[ J ]. J Control Release, 1999,58 ( 1 ) : 29 - 38.
  • 7杨惠娣,徐彬.氨溴索的作用机制及临床应用[J].中国医院药学杂志,2002,22(1):44-45. 被引量:207
  • 8佟娟.氨溴索治疗慢性喘息型支气管炎疗效观察[J].中国煤炭工业医学杂志,2006,9(9):933-933. 被引量:3
  • 9LAOAG-FERNANDEZ JB, FERNANDEZ AM,MARUO T. Ante natal use of ambroxol for the prevention of intant respiratory dis tress syndrome [ J ]. J Obstet Gynaecol Res, 2000,26 ( 4 ) : 307 - 312.
  • 10国家药典委员会编.中华人民共和国药典[S].2010年版.二部.北京:中国医药科技出版社,2010:附录XC.

二级参考文献5

共引文献261

同被引文献41

  • 1张颖,高永良.环糊精及其衍生物在眼用制剂中的应用[J].国外医学(药学分册),2006,33(2):143-147. 被引量:3
  • 2吴纯洁,齐红艺,黄春燕,苏诚,侯世祥.羟丙基-β-环糊精对葛根素溶解性与角膜渗透性的影响[J].中国药学杂志,2006,41(20):1565-1568. 被引量:3
  • 3欧阳斌,刘科秋.渗透泵制剂的研究进展[J].中国药房,2007,18(28):2227-2228. 被引量:5
  • 4Okimoto K, Tokunaga Y, Ibuki R, et al. Applicability of (SBE) 7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs) [J]. Int J Pharm, 2004, 286(1/2): 81-88.
  • 5Liu R, Liu Z D, Zhang C Q et al. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcomeal permeation [J]. J Pharm Sci, 2011, 100(8): 3186-3195.
  • 6Kesavan K, Kant S, Singh P N, et al. Effect of hydroxypropyl-β-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydro gel [J]. Curr Eye Res, 2011, 36(10): 918-929.
  • 7Zhang H, Chen M, He Z, et al. Molecular modeling-based inclusion mechanism and stability studies of doxycycline and hydroxypropyl-β-cyclodextrin complex for ophthalmic delivery [J]. AAPS Pharm Sci Tech, 2013, 14(1): 10-18.
  • 8Tanito M, Ham K, Takai Y, et al. Topical rnicroparticle eye drops for diabetic macular edema [J]. lnvest Ophthalmol Vis Sci, 2011, 52(11): 7944-7948.
  • 9Delong M A, Sturdivant J M, Royalty S M. Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds: US, 2014024920113/ 442263 [P]. 2012-04-09.
  • 10Malaterre V,Ogorka J,Loggia N,et al.Oral osmotically driven systems:30 years of development and clinical use[J].Eur J Pharm Biopharm,2009,73(3):311-323.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部